Spreng Capital Management Inc. Sells 3,081 Shares of Johnson & Johnson (NYSE:JNJ)

Spreng Capital Management Inc. reduced its position in Johnson & Johnson (NYSE:JNJFree Report) by 18.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,595 shares of the company’s stock after selling 3,081 shares during the period. Johnson & Johnson makes up 1.3% of Spreng Capital Management Inc.’s investment portfolio, making the stock its 15th largest holding. Spreng Capital Management Inc.’s holdings in Johnson & Johnson were worth $2,131,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Hibernia Wealth Partners LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth $27,000. FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth $37,000. Tower View Wealth Management LLC raised its position in Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares during the last quarter. Creative Capital Management Investments LLC raised its position in Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at $48,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 0.3 %

Shares of JNJ opened at $157.78 on Tuesday. The business has a 50-day moving average of $158.58 and a 200 day moving average of $156.57. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The firm has a market cap of $380.22 billion, a P/E ratio of 11.43, a price-to-earnings-growth ratio of 2.66 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. During the same quarter last year, the firm posted $2.35 EPS. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. As a group, research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

Analyst Ratings Changes

JNJ has been the subject of a number of analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Finally, Morgan Stanley decreased their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $177.31.

View Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.